| 研究报告 |
|
|
|
|
| S100A9促进肝癌细胞HepG2的存活与侵袭依赖于RAGE |
| 武睿1, 周兰2, 崔鲂1 |
1. 重庆医科大学附属第一医院 重庆 400016;
2 重庆医科大学检验医学院 重庆 400016 |
|
| S100A9 Promotes Human Hepatocellular Carcinoma Cell HepG2 Proliferation and Invasion Involving RAGE |
| WU Rui1, ZHOU Lan2, CUI Fang1 |
1. The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;
2. Chongqing Medical University, Chongqing 400016, China |
|
[1] Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol, 2001, 33(7): 637-668.
[2] Saleem M, Kweon M H, Johnson J J, et al. S100a4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proceedings of the National Academy of Sciences of the United States of America, 2006,103(40):14825-14830.
[3] Benedyk M, Sopalla C, Nacken W, et al. HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9 show increased NADPH oxidase and NF-kappaB activities. J Invest Dermatol, 2007, 127(8): 2001-2011.
[4] Markowitz J, Carson W E 3rd. Review of s100a9 biology and its role in cancer. Biochimica et Biophysica Acta, 2013,1835(1):100-109.
[5] Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun, 2012, 4(1):31-40.
[6] Salama I, Malone P S, Mihaimeed F, et al. A review of the S100 proteins in cancer. Eur J Surg Oncol, 2008, 34(4): 357-364.
[7] Duan L, Wu R, Ye L, et al. S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/beta-Catenin pathway. PLoS One, 2013, 8(4): e62092.
[8] Arai K, Yamada T, Nozawa R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol, 2000, 17(3): 183-188.
[9] Nemeth J, Stein I, Haag D, et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology, 2009, 50(4): 1251-1262.
[10] Riehl A, Nemeth J, Angel P, et al. The receptor rage: Bridging inflammation and cancer. Cell Commun Signal, 2009,7(10):12.
[11] Taguchi A, Blood D C, del Toro G, et al. Blockade of rage-amphoterin signalling suppresses tumour growth and metastases. Nature, 2000,405(6784):354-360.
[12] Hiwatashi K, Ueno S, Abeyama K, et al. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol,2008,15(3):923-933.
[13] Cheng P, Dai W, Wang F, et al. Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways. Biochem Biophys Res Commun,2014,443(4):1162-1168.
[14] Chen R C, Yi PP, Zhou R R, et al. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem,2014,390(1-2):271-280.
[15] Takino J, Yamagishi S, Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol,2012,18(15):1781-1788.
[16] Hofmann M A, Drury S, Fu C, et al. Rage mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell, 1999,97(7):889-901.
[17] Dattilo B M, Fritz G, Leclerc E, et al. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry, 2007,46(23):6957-6970.
[18] Ghavami S, Rashedi I, Dattilo B M, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MA Pkinase-dependent pathway. J Leukoc Biol, 2008, 83(6): 1484-1492.
[19] 游莉,徐兰兰,郭元元,等.GST-hS100A9 融合蛋白的原核表达、纯化及鉴定.中国生化药物杂志,2011,32(4): 253-256. You L, Xu L L, Guo Y Y,et al. Prokaryotic expression, purification and identification of GST-human S100A9 fusion protein. Chinese Journal of Biochemical Pharmaceutics,2011,32(4): 253-256.
[20] Yang J D, Nakamura I, Roberts L R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol, 2011, 21(1):35-43.
[21] Geetha S. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun, 2012, 4(1):31-40.
[22] Salama I, Malone P S, Mihaimeed F, et al. A review of the S100 proteins in cancer. Eur J Surg Oncol, 2008, 34(4): 357-364.
[23] Ito Y, Arai K, Ryushi, et al. S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol Res Pract, 2005, 201(8-9):551-556.
[24] 朱红,刘丽,刘欢,等. Galectin-7和S100A9表达与宫颈鳞癌发生发展的相关性.中南大学学报(医学版), 2013,9(38): 888-895. Zhu H, Liu L, Liu H, et al. Expression of galectin-7 and S100A9 and development of cervical squamous carcinoma.Journal of Central South University: Medical Science, 2013,9(38): 888-895.
[25] 吴慧玲,董盛宇,叶耀耀,等. S100蛋白表达与鼻咽癌临床关系的研究.中国现代医药杂志, 2013, 15(5): 15-18. Wu H L,Dong S Y, Ye Y Y, et al. The expression and clinical significance of S100 protein family in nasopharyngeal carcinoma.Modern Medicine Journal Of China, 2013,15(5): 15-18.
[26] Hermani A, De Servi B, Medunjanin S, et al. S100A8 and S100A9 activate MA Pkinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res, 2006, 312(2): 184-197.
[27] Moon A, Yong H Y, Song J I, et al. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res, 2008,6(10): 1544-1553.
[28] Yaser A M, Huang Y, Zhou R R, et al. The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci, 2012, 13(5): 5982-5997.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
